EWTX

Edgewise Therapeutics (EWTX)

About Edgewise Therapeutics (EWTX)

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Details

Daily high
$28.34
Daily low
$27.18
Price at open
$27.90
52 Week High
$38.12
52 Week Low
$9.00
Market cap
2.7B
Dividend yield
0.00%
Volume
199,320
Avg. volume
947,045
P/E ratio
-19.27

Edgewise Therapeutics News

Details

Daily high
$28.34
Daily low
$27.18
Price at open
$27.90
52 Week High
$38.12
52 Week Low
$9.00
Market cap
2.7B
Dividend yield
0.00%
Volume
199,320
Avg. volume
947,045
P/E ratio
-19.27